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The ubiquitous second messenger cyclic adenosine
3 0,5 0-monophosphate (cAMP) plays a key role in the
intracellular signaling pathways of hormones, neuro-
transmitters, odorants, and autacoids.1 The synthesis
of cAMP from ATP is catalyzed by adenylyl cyclase
(AC) enzymes. Mammalian adenylyl cyclases (mACs)
are a family of integral membrane proteins with at least
nine isoforms, each regulated in a unique fashion by
association with the stimulatory G protein a subunit
(Gas), cofactor binding of the diterpene forskolin
(FSK) and its soluble derivatives (except for type IX),
exposure to Ca2+, and protein phosphorylation.2 In
addition to evidence suggesting correlations between ele-
vated AC activity and contractile dysfunction in human
heart failure,3 suppressing the function of AC isoform 5
(i.e., AC5) has been found to provide substantial protec-
tion against myocardial apoptosis arising from cardiac0968-0896/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2007.02.014
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 These authors contributed equally to this work.pressure overload in a mouse model.4 Both eﬀects imply
the potential importance of AC inhibition as a mode of
preventing heart failure. AC inhibitors may also be
potentially used for treatment of cancer,5 psychosis,6
and for the purposes of contraception or treatment of
male infertility.7,8
ACs contain 12 transmembrane helices, and two intra-
cellular lobes generally referred to as C1 and C2. The
nucleotide-binding site of the protein consists of two
homologous cytoplasmic domains, C1a and C2a, within
the intracellular lobes. These two domains are com-
prised of approximately 230 amino acids that share at
least 50% similarity across the AC family and are struc-
turally similar.9 Previous mutagenesis analysis revealed
that residues from both C1a and C2a domains contribute
to ATP binding and catalysis.10,11 Recent X-ray crystal
structures of the catalytic site9,12 provide further insight
into AC catalysis and inhibition, collectively illuminat-
ing a receptor that can be characterized as having three
main features: (1) a phosphate binding region contain-
ing two metal ions (typically Mg2+ or Mn2+), (2) a pur-
ine ring binding site possessing H-bond donating and
accepting side-chains suitably oriented for aﬃxing aden-
osine, and (3) a hydrophobic pocket.
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is apparent that ACs exist in at least three conforma-
tional states: (1) a catalytically inactive state, (2) an
active state unbound by activators such as forskolin
and Gas, and (3) an active substrate-bound state. In
addition to chain ﬂexibility, key structural diﬀerences
arise from the relative orientation of the associated C1
and C2 lobes. Comparing the relative C1/C2 orientation
within a forskolin-bound C1ÆC2 heterodimer on one
hand, with the C2/C2 orientation in a C2ÆC2 homodimer,
one observes a 7 inter-lobe rotational diﬀerence. The
rotational state of the former brings key catalytic
elements from the two domains about 2 A˚ closer to each
other. It is reasonable to conclude that in each of the
above cases at least some of the observed structure
diﬀerences arise from AC interactions with forskolin
and G-protein subunits, and that these interactions
thus dynamically alter binding mechanics within the
nucleotide receptor.
Many inhibitors to the AC nucleotide receptor, includ-
ing numerous nucleotides and nucleotide analogs, also
induce AC structural relaxation. So-called p-site inhibi-
tors exhibit non-competitive inhibition by initiating a
transition in the C1ÆC2 moiety from an ‘open’ to a
‘closed’ conformation. This transition entails the a1–
a2, b2–b3, and a3–b4 loops of C1 and the b7 0–b8 0 loop
of C2 moving toward each other, thus closing the gap
between the purine-binding pocket in the C2 domain
and the triphosphate binding loop (P-loop) located pri-
marily in the C1 domain.
9,14 Recently, we have identiﬁed
novel competitive nucleotide AC inhibitors with
N-methyl-anthranoyl (MANT) substituents on ribosyl
hydroxy oxygens.15 A crystal structure of the AC com-
plex with MANT-GTP (Ki = 4.2 nM) has revealed thatTable 1. Comparison of predicted inhibition constants for our training se
measured in excess Mn2+16
Nucleotide Ki (nM; expt.) pKi (exp
MANT-GTP 4.2 8.38
MANT-ITPcS 19 7.72
MANT-AppNHp 20 7.70
MANT-GTPcS 24 7.62
MANT-GppNHp 34 7.47
MANT-ATP 35 7.46
2 0-d-30-MANT-GTP 45 7.35
MANT-ADP 57 7.24
2 0-d-30-MANT-GppNHp 200 6.70
MANT-GDP 290 6.54
MANT-XppNHp 330 6.48
2 0-d-30-MANT-ATP 460 6.34
ITPcS 1200 5.92
BODIPY-FL-GppNHp 1400 5.85
2 0-d-30-MANT-GDP 3400 5.47
MANT-XDP 5800 5.24
UTPcS 8500 5.07
6-MAH-cAMP 43,000 4.37
BODIPY-FL-GTPcS 79,000 4.10
2 0-d-UTP 100,000 4.00
MANT-cAMP 100,000 4.00
MANT-cGMP 100,000 4.00
UTP 100,000 4.00
pKi = 9  log10 (Ki).the MANT group binds to a conserved hydrophobic
patch near the center of the cavity, and prevents mACs
from undergoing the ‘open’ to ‘closed’ transition.14,16 In
the present paper, we will focus on the characterization
of the purine and pyrimidine MANT-nucleotide inhibi-
tion mode, determining whether it, too, may induce
structural relaxation eﬀects in the receptor, and identify-
ing trends favoring potent AC inhibition.2. Results and discussion
2.1. Ribosyl-substituted nucleotides
MANT-GTP is one of the most potent known AC
inhibitors, binding to the nucleotide binding site with
a Ki of 4.2 nM.
16 While the MANT group, on average,
enhances inhibitive potency relative to NRM nucleo-
tides,15 substantial variations in aﬃnity also occur as a
function of the purine/pyrimidine rings and modiﬁca-
tions to the phosphate tail. To explore structure-activity
relationships among MANT-nucleotide inhibitors of
AC, we applied our modiﬁed COMBINE approach to
the prediction of bound state conformers, Ki-values,
and interaction coeﬃcients for the set of ligands listed
in Table 1. In doing so, we were able to achieve bound
conformers whose interactions were reasonably consis-
tent with experimental Ki-values for 21 of the 23 ligands
in the test set, with only ITPcS and MANT-XDP failing
to yield a plausible docked conformer. The most proba-
ble explanations for these outlier cases include either
error in the experimentally determined aﬃnity or possi-
ble post-complexation relaxation eﬀects that are not well
reﬂected in the 1TL7 crystal structure used as a receptor
model. The set of bound ligand conformers used in thet of AC inhibitors versus previously published experimental data as
t.) pKi (pred.) Predicted ribose substitution
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Figure 2. Predicted values for our eight-compound test set composed
of 7 TNP-nucleotides, plus MANT-EDA-ATP, plotted relative to
experimental values. These predictions are overlaid with the correla-
tion curve and 95% conﬁdence interval derived from the training set
(see Fig. 1), revealing that the bioactivity trend for the test set
predictions correlates well qualitatively with that of the training set,
but tends to overestimate bioactivity.
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Supplementary material. These conformers correspond
well to experimental data, with a trained three-compo-
nent PLS ﬁt displaying strong correlation (R2 = 0.89)
and a reasonable leave-one-out cross-validation
(Q2 = 0.61) score. It should be noted that coeﬃcients
on the desolvation terms DPSA and DNPSA were found
to be very small and that their omission yielded a model
with nearly identical behavior relative to the ﬁrst, with
R2 and Q2 values and most pKi predictions only varying
in the second or third decimal places (Fig. 1).
In order to provide an independent test of model predic-
tivity, a series of seven trinitrophenol (TNP) substituted
nucleotide analogs (TNP-ATP, TNP-ADP, TNP-AMP,
TNP-GTP, TNP-GDP, TNP-UTP, and TNP-CTP,
respectively) and one MANT-substituted species with
an aminoethyl-carbamoyl (EDA) linker to the ribosyl
(MANT-EDA-ATP), whose structures and AC inhibi-
tion activity are reported in recent work by Mou et al.
were studied.17 Our calculations attained a strong degree
of qualitative correlation with the experimental data
(R2 = 0.76; see Fig. 2), accurately reproducing the general
activity trend. From Figure 2, one does observe a
consistent trend by our method toward overestimating
the aﬃnity of these test set molecules.
From the COMBINE training process, we have ascer-
tained that the 3 0-ribose substituents are preferred over
the 2 0-analogs in the majority of cases. Of the 11 ligands
for which autoconversion is possible between ribose sub-
stitution points, eight were found to adopt the 3 0-substi-
tution form and only MANT-AppNHp and the two
BODIPY species are predicted to retain a 2 0-substituent.
In prior pharmacophoric studies of the AC system, a
number of receptor residues have been qualitatively
identiﬁed as providing features for interaction with ob-
served inhibitors. These include: Gly 399, Phe 400, ThrFigure 1. Correlation between experimental and predicted pKi values
for ribosyl-substituted nucleotides interacting with Mn2+ enriched AC.
Best ﬁt linear regression curve is shown (solid line; R2 = 0.89;
Q2 = 0.61), plus 95% conﬁdence intervals.401, Leu 438, and Asp 440 (all C1 constituents), as well
as Lys 938, Asp 1018, Leu 1019, Gly 1021, Asn 1022,
Asn 1025, Ser 1028, Arg 1029, and Leu 1065 (all
C2).
9–16,18 COMBINE analysis allows one to augment
such intuitive insight by exposing other residues that,
although possibly exerting smaller average eﬀects on
ligand aﬃnity, may discriminate between strong and
weak ligands more eﬀectively than the above highly con-
served interactions, thus providing new avenues for
inhibitor reﬁnement. To this end, those residues with
optimal tendencies toward ligand discrimination (as
judged by absolute magnitude of the PLS coeﬃcient
and relative proximity to the P-site) are indicated in
Figure 3 as a function of their COMBINE coeﬃcients,
and their corresponding interaction enthalpy (E) and
coeﬃcient * E information are reported in Table 2. As
a complement to this, a depiction of the average phar-
macophore arising from the full set of 21 bound ligand
conformers is provided in Figure 4 against the backdrop
of those discriminatory residues identiﬁed in Figure 3.
Figure 4 provides a clear qualitative depiction of the
three-point pharmacophore model recently described
for AC inhibition,19 wherein the ligand binding mode
is dominated by three main features: (1) a triphosphate
binding region rendered as a predominantly red (anion-
ic) lobe at the bottom of the graphic, (2) a mixed red/
blue (H-donor/H-acceptor) polar region in the inner
region of the top part of the graphic corresponding to
the purine base binding site, and (3) the predominantly
yellow hydrophobic pocket (outer top region). The
interactions corresponding to these pharmacophore
elements are described in the succeeding subsections.
2.1.1. Triphosphate binding region. The phosphate tails
of these nucleotide ligands interact primarily with two
Figure 3. COMBINE coeﬃcients for the ten residues of greatest
importance to discriminating ligand binding aﬃnities as a function of
van der Waals (a) and electrostatic (b) interactions. Selected residues
are those residues within 8 A˚ of the ligand binding site that possess the
ten largest COMBINE coeﬃcients. The signs of coeﬃcients charac-
terize whether the observed aﬃnity trend correlates (negative sign) or
anticorrelates (positive) with a speciﬁc ligand-residue interaction.
Large coeﬃcient magnitude results when the COMBINE model
accentuates the role of a given interaction in distriminating binding
aﬃnity.
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middle phosphates (a and b) electrostatically couple
with metal A, while the terminal (c) phosphate of tri-
phosphate ligands coordinates with metal B. The strong
triphosphate binding aﬃnity relative to di- and mono-Table 2. Ligand-residue coeﬃcients, interaction enthalpies (E), and produc
Figure 3
Interaction Coeﬀ. E (vdW) Coeﬀ. * E
Leu 438 0.037 6.805 0.253
Lys 436 0.032 0.060 0.002
Thr 939 0.031 0.049 0.002
Ile 937 0.013 0.114 0.001
Glu 518 0.027 1.421 0.038
Ala 395 0.025 0.058 0.001
Leu 412 0.025 0.032 0.001
Asp 396 0.025 4.787 0.120
Gly 439 0.024 1.697 0.040
Glu 398 0.023 0.301 0.007
DH corresponds to the average enthalpy over the full set of training set ligaphosphates may result from a very favorable binding
environment involving ionic interactions with NH3
þ of
Lys 1065, and hydrogen bond donor sites from the
backbone NHs of the Thr 401 and Phe 400. Of these
three features, only Thr 401 is listed as one of the most
important discriminatory residues according to COM-
BINE coeﬃcients, which implies that the others support
interactions that are relatively uniformly conserved
among the ligand manifold. Instead, in addition to
Thr 401, the residues that appear to inﬂuence selectivity
are Ala 395, Asp 396, Ile 397, Glu 398, and Glu 518.
Among these, Ile 397 has a clear signiﬁcance: its large
negative electrostatic coeﬃcient indicates that it is an
unfavorable interaction site for negatively charged
ligands largely because it orients a backbone carbonyl
toward the phosphate binding site, and its large negative
VDW coeﬃcient implies that it provides an unfavorable
surface for hydrophobic interactions. Thus, any ligand
that approaches close to Ile 397 (as might be the
case for species with bulky groups attached to the purine
or ribose) is expected to be a poor AC inhibitor. The
nearby Ala 395 is also unfavorable for non-polar
interactions.
Interestingly, the three anionic residues identiﬁed above
from COMBINE analysis (Asp 396, Glu 398, and Glu
518) actually derive their importance from VDW inter-
actions rather than electrostatics. This correlation is
likely somewhat artiﬁcial: the main enzymatic role of
these residues is in inducing the receptor cations (the
two metal ions and Lys 1065) to be positioned favorably
for attracting the anionic phosphate tail. A ligand bind-
ing mode close to these cations thus corresponds to suf-
ﬁcient proximity to the receptor’s partner anions to
register a ‘favorable’ van der Waals interaction, which
is plausible since van der Waals interactions generally
have a longer-range inﬂuence than electrostatics, as
has been reported elsewhere for metastable ion–ion
attractions.20
2.1.2. Nucleotide base binding site. The purine ring bind-
ing site is mainly hydrophobic, but does support
H-bonding or electrostatic interactions capable of dis-
tinguishing among diﬀerent purine or pyrimidine rings.
Immediately adjacent to the purine or pyrimidine rings
is a surface formed by exposed backbones of Leu 438
and Gly 439 providing complementary electrostaticts of the coeﬃcient and E for those important residues identiﬁed in
Interaction Coeﬀ. E (ele) Coeﬀ. * E
Asp 1018 0.021 4.930 0.105
Gly 1021 0.017 0.365 0.006
Val 1024 0.017 0.315 0.005
Leu 438 0.016 1.178 0.019
Thr 401 0.016 1.563 0.025
Leu 412 0.015 0.179 0.003
Phe 889 0.015 0.075 0.001
Ala 404 0.015 0.546 0.008
Ile 397 0.014 6.462 0.092
Gly 439 0.012 0.939 0.010
nds.
Figure 4. Front (left side) and back (right side) views of the cumulative pharmacophore resulting from all 21 ribose-modiﬁed AC inhibitors
superimposed in their predicted docked conformers within the framework of the AC receptor. Each ligand is rendered as a dotted Connolly surface,
colored to reﬂect hydrophobic surfaces (yellow), polar electropositive (blue), and polar electronegative (red). Key receptor residues, as deﬁned by
close proximity to the binding site and by larger COMBINE coeﬃcients, are rendered in stick form and colored according to the standard CPK
scheme.
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the guanine ring in bound MANT-GTP do so via
VDW interactions, the base does form H-bonds to
Lys 938, Asp 1018 and Ile 1019. Thr 939 does not have
a direct contact with the purine, but appears to exert a
substantial non-local inﬂuence as gauged by its sub-
stantial COMBINE coeﬃcient in Figure 3. One may
surmise that ATP analogs have substantially weaker
interactions with the purine subsite than do GTP ana-
logs. This would be a reasonable behavior for a sub-
strate such as ATP that, catalytically, should be
expected to have only modest barriers to receptor evac-
uation as the cAMP product. This would also explain
observations of substantially greater aﬃnity for
MANT-GTP and GTPcS relative to MANT-ATP and
ATPcS.16,18,21 They do not, however, explain why the
adenine analogs of other, non-triphosphate, systems
(e.g., AppNHp, MANT-AppNHp, MANT-ADP) are
frequently more potent inhibitors than their guanine
analogs. Our simulations suggest, however, that in
some cases the adenine ring may be energetically most
favorable when rotated 180 relative to the conforma-
tion observed crystallographically for MANT-ATP.14
In doing so, the ring recoups H-bonds with Asp 1018,
and Ile 1019 (although not with Lys 938) that could
eﬀectively negate most of the aﬃnity advantage other-
wise observed for guanine analogs. While our docking
studies do suggest that this ﬂipped adenine ring is fea-
sible even for MANT-ATP, it may be most evident for
ligands with less optimal anionic tail groups (i.e., non-
triphosphates). The potential beneﬁts of this alternative
orientation may be further augmented in the case of
MANT-AppNHp by the possible positioning of the
MANT at the 2 0 position on the ribose.
Among the other residues within the purine binding
pocket identiﬁed as potentially important via our COM-
BINE analysis, most appear to inﬂuence primarily via
electrostatics, where the Gly 1021 carbonyl is considered
a favorable target for electrostatic coupling with ligand
electropositive groups, and the backbone amide protons
of Gly 439 and Val 1024 appear to be attractive to elec-tronegative species. Phe 889 does not orient its back-
bone toward the purine, thus one may surmise that the
fairly large electronegative COMBINE coeﬃcient is a
spurious product of noise in the model.
2.1.3. Hydrophobic pocket. This pocket is an important
region for considering ligand modiﬁcations for the pur-
pose of optimizing inhibitor potency, with numerous
hydrophobic VDW contacts potentially available in this
area, the most important of which are likely Ala 409,
Asn 1022, Gly 1021, Trp 1020, Val 413, Leu 412, Ala
404, and Phe 400. Whereas prior modeling studies15,16
have suggested that the 2 0-MANT is more favorable than
3 0-MANT position, our COMBINE analysis herein, as
well as recent crystallographic data14 and the 10-fold
poorer aﬃnity of 2 0-d-3 0-MANT-GTP (Ki, 45 nM) rela-
tive toMANT-GTP (Ki, 4.2 nM), all argue for theMANT
to be in the 3 0 position. This preference appears to result
from a receptor conformational change, as evidenced by
comparisons of crystal structures for the AC/ATPaS
and AC/MANT-GTP complexes.
Reliable COMBINE-based ranking of speciﬁc pharma-
cophoric elements in the hydrophobic pocket is compli-
cated by the fact that coeﬃcients for these residues are
comparatively small. This arises primarily from poor
conservation of the ligand binding mode in this pocket.
Speciﬁcally, variations within the rest of the molecule,
such as the length or chemical constitution of the phos-
phate tail, location of ribose modiﬁcation, and the pres-
ence or absence of monophosphate cyclization and
partial deoxiﬁcation of the ribose, all seem to have sub-
stantial impact on the orientation of the hydrophobic
ribose substituent, even when that substituent (such as
MANT) is conserved across a set of ligands. More intu-
itive detail would be available from a COMBINE model
derived by training to inhibition data for a ligand set
wherein the primary source of diversity arises from var-
ied ribose substitution, while the phosphate tail and pur-
ine structures were kept largely consistent.
Unfortunately, no such data set of statistically tenable
size is yet available.
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In previous AC inhibition analysis we performed similar
docking and COMBINE analysis on a set of NRM pur-
ine and pyrimidine nucleotides that varied as a function
of modiﬁcations on the base or the phosphate.18 The
resulting bound conformers for the 17 species studied
therein provide useful points of comparison relative to
the ribosyl-substituted analogs and are thus depicted
in Figure 5. These ligands occupy the ATP binding site
with the phosphate tail coordinating with metal ions,
and the nucleotide bases binding to the purine subsite.
Across the set, ligand conformations are very similar
to the crystallographically determined ATPaS conform-
er,22 whereby the adenine NH2 group is located 2.99 A˚
from the side-chain oxygen of the Asp 1018, and
3.05 A˚ from the NH3+ of Lys 938. The ribosyl oxygens
interact electrostatically with the side-chain O of Ser
1028 (3.86 A˚ distant) and the side-chain nitrogen of
Asn 1025 (4.16 A˚). c-Thiophosphate analogs were pre-
dicted to interact more strongly with receptor metal B,
and appear to form shorter H-bonds with the Gly 399
backbone NH and Lys 1065 side-chain NH3+ because
of a longer P–S bond length. Structural analysis suggests
that phosphoamidate tails apparently do not create
additional H-bonds, and also do not lead to shorter
or stronger interactions between the phosphate with
receptor metal ions or other residues. Consequently, it
is not surprising to ﬁnd that NppNHps are less potent
inhibitors than NTPcSs.
Our recent work also reported COMBINE analysis for
the NRM species.18 While much of the analysis need
not be reiterated herein, some key trends are very note-
worthy with respect to their diﬀerence relative to our
studies on ribosyl-modiﬁed analogs herein. The key dis-
tinction is that while residues near the ligand phosphateFigure 5. Computationally predicted conformers for the full training set o
work,18 all bound within the AC active site corresponding to the Mn2+-enrich
the receptor, only selected key residues are depicted, as space-ﬁlling models
blue, electropositive; white, polar/neutral. Ligands are depicted in stick form
yellow, S; orange, P. Metal ions are depicted as magenta spheres.tail appeared to play little role in diﬀerentiating relative
potency in the current study of ribosyl-substituted
nucleotides, all 20 of the residues most signiﬁcant to
NRM nucleotide binding are clustered near the phos-
phate.18 This suggests that much greater NRM ligand
aﬃnity variation occurs as a function of phosphate tail
modiﬁcations than from diﬀerences in the purine or
pyrimidine base. As suggested earlier, other receptor
features, most notably the hydrophobic pocket, appear
to play the key roles in aﬃxing ribose-substituted species
and, in the case of MANT nucleotides, establishing their
inhibitive superiority.
Figuring prominently among the phosphate-binding res-
idues are the two receptor metal ions of relevance to
NRM nucleotides. Metal ion interactions thus provide
clear points of diﬀerentiation among the various inhibi-
tors, regardless of whether the AC had been exposed
to Mg2+ rich or Mn2+ rich media. It is interesting to note
that metal A contributes more to VDW interactions,
whereas B’s contribution is more slanted toward electro-
statics. The latter may be due to close coupling between
metal B and all three phosphoanionic centers, whereas
metal A interacts closely with only the a-phosphate.
Since some single phosphate (NMPs) species do exhibit
marginal inhibition of the AC nucleotide site, metal A
must still serve key roles in both VDW and electrostatic
coupling.
For NRM nucleotides, an electrostatic contribution
from Asp 440 also appears on the list of signiﬁcant
residues in both the Mn2+ and Mg2+ enriched cases.18
Since it is located closest to the ligand anionic phosphate
tail, Asp 440 likely makes a negative contribution to the
net binding in most cases, with its role in diﬀerentiating
ligands being a question of how close the ligand is forced
to approach the aspartate carboxyanion. It may bef 17 purine and pyrimidine NRM nucleotides reported in our recent
ed species as crystallized in conjunction with the ATPaS ligand. Within
colored as follows: yellow, hydrophobic surface; red, electronegative;
, with the following color scheme: red, O; gray, C; white, H; blue, N;
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substituents that can take advantage of this strong
acceptor.
It should be noted that among NRM species, the ribose
itself does not appear to engage in strong interactions
with the receptor. In the ATPaS case, the ribose does
not engage in any plausible H-bonding, although the
side-chain oxygen of Ser 1028 does interact electrostati-
cally with the 2 0 hydroxyl, 3 0 hydroxyl, and 5 0 furanyl
oxygens on the ribose, via distances of 4.73, 3.45, and
3.89 A˚, respectively. A side-chain N on Arg 1029 is also
located within 4.25 A˚ of the 3 0 hydroxyl.
2.3. Receptor ﬂexibility
Variations in receptor conformations as a function of
diﬀering inhibition state frequently involve torsional
ﬂexibility among side chain residues in the receptor
region. To some extent this occurs in the AC case in
comparing the crystallographically determined binding
modes of ATPaS18 and MANT-GTP.14 Within the pur-
ine binding site, for example, Lys 938 plays a diﬀerent
role in the MANT-GTP binding than it does for
ATPaS: the side chain NH3
þ position diﬀers by 2.3 A˚
between the two structures, coupling with the purine
ring via nitrogen interaction on ATPaS but via oxygen
on MANT-GTP. In the phosphate binding region, the
Arg 1029 side-chain also has signiﬁcant torsional mo-
tion around Cc-Cd bond, with the position of terminal
nitrogens diﬀering by about 6.1 A˚ from one structure
to the other, forming an H-bond to the phosphate of
ATPaS, but not for MANT-GTP. To check the energy
cost for such movement in Arg 1029, a dihedral energy
plot was calculated and is shown in Figure 6. In the
AC/MANT-GTP crystal structure, the torsion is in
one low energy region around 66.2, whereas the value
for the ATPaS bound structure is within another low
energy region located between 130 and 180.Figure 6. The dihedral energy plot for the Cb–Cc–Cd–Ne torsion angle
of Arg 1029. The dashed vertical line indicates the crystallographically
observed value (66.2). The high barrier from 50 to 100 reﬂects a
direct clash with Ser 1032, Thr 1033, and nearby residues, whereas the
small barrier from 180 to 66 indicates weaker VDW interaction
with Asn 1063, Val 1064, and Lys 1065. The energy was calculated in
the AC crystal structure corresponding to the bound MANT-GTP
case, but with MANT-GTP removed.It is also apparent from the two crystal structures that
the side-chain of Asn 1025 has a diﬀerent conformation
in the presence of ATPaS than it does for the MANT-
GTP bound conformation, and that the latter will per-
mit favorable interaction with the oxygen in the position
3 0 of the ribose ring, as was consistent with our analysis
of ribose-substituted nucleotides binding to the receptor
in the MANT-GTP bound conformation. This Asn 1025
ﬂexibility suggests a possible avenue for further optimi-
zation of MANT inhibitors: Replacing the MANT
methyl group with a longer H-bond acceptor (e.g.,
CH2OH) might increase the aﬃnity by permitting inter-
actions with the Asn 1022 side chain NH2 (currently
4.05 A˚ from the methyl).
It would appear that not all of the diﬀerences between
the crystal structures of MANT-GTP inhibited AC
and the ATPaS bound system arise from side-chain
relaxations, however. While the all-atom RMSD values
between the two superimposed structures are 1.23 A˚ for
chain A and 1.11 A˚ for chain B, the net deviations are
quite similar when comparing Ca atoms (0.90 A˚ for
chain A and 0.70 A˚ for B) and the corresponding back-
bone atoms (0.92 and 0.72 A˚, respectively). This is tan-
gible evidence of the subtle but non-trivial structural
dependence on AC ligation state that has been suggested
previously.7,14,22,23 It also suggests that any serious
attempt to design optimal AC inhibitors should explicit-
ly consider these diﬀerences.
From crystallographic analysis, it is apparent that the
MANT-GTP bound AC has a conformation somewhere
between the open and closed states.14 The most obvious
structural diﬀerence of this system relative to that of
NRM inhibitors such as ATPaS is in the MANT bind-
ing region. In the ATPaS bound conformation, the posi-
tions of Asn 1025 (both main and side-chains) and the
phenyl ring of the Phe 400 collectively form a narrow
gorge with closest inter-atomic spacing of 3.36 A˚. In this
case, a strong steric hindrance would clearly prevent
groups such as the MANT from binding. In the
MANT-GTP crystal structure, however, the spacing is
no less than 7.06 A˚ throughout, which constitutes suﬃ-
cient space for MANT entry into the pocket.
To further verify the inﬂuence of the conformation
change of the AC on the binding aﬃnity of ribose-
substituted and NRM nucleotides, we attempted to (a)
dock MANT-substituted nucleotides into the receptor
from the AC/ATPaS crystal structure, and (b) dock
NRM nucleotides into the receptor from the AC/
MANT-GTP structure. In the ﬁrst case, the computa-
tions all failed. This indicates that without some form
of receptor conditioning (as was performed in a prior
study using molecular dynamics simulations),16 the
receptor structure suitable for binding NRM species is
not conducive to MANT-ligand binding, largely as a
result of steric hindrance arising from Asn 1025 and
Phe 400. In the second case, the NRM nucleotides did
successfully bind within the receptor. However an ensu-
ing COMBINE analysis yielded poor correlation
relative to experimentally determined assay data. Given
the high quality COMBINE correlation achieved for
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R2 = 0.93, Q2(LOO) = 0.71 for excess Mn2+; R2 = 0.89,
Q2 = 0.75 for Mg2+),18 it appears fairly certain that the
latter failure is also due to diﬀerences in AC receptor
structure between the two models. It is our assertion
that a strong lipophilic aﬃnity between theMANTgroup
and the hydrophobic pocket is capable of inducing the
conformational diﬀerences observed in comparing the
two structures.3. Conclusions
The COMBINE methodology provides an excellent
strategy for performing detailed structure–activity
relationship analysis for targets where both experimen-
tal inhibition data and a receptor crystal structure are
available. In this study, we have employed COMBINE
analysis to derive consistent conformational predictions
for a variety of ribose-substituted nucleotides bound to
the AC nucleotide binding site, achieving a model with
strong correlation relative to experiment (R2 = 0.89)
and reasonable cross-validated predictivity (Q2 = 0.61).
To augment prior SAR analyses based largely on crystal
structure inspection and low-level modeling studies, our
COMBINE model highlights a number of residues that
may serve key roles in diﬀerentiating the relative ligand
aﬃnity and inhibitive potential. In the triphosphate
binding site, such residues include Thr 401, whose back-
bone NH provides an important H-donor site for the
phosphate tail, and Ile 397 and Ala 385, both of which
are considered to be unfavorable sites for van der Waals
contact. In the purine binding pocket, residue impor-
tance is dictated largely by electrostatics, with the back-
bone carbonyl providing a potential beneﬁcial
H-acceptor site, and the backbone amide protons of
Gly 439 and Val 1024 oﬀering prospective H-donation
targets. Our COMBINE analysis was not eﬀective in
resolving pharmacophoric trends within the hydropho-
bic pocket, largely due to non-conservation of binding
modes by lipophilic ribose substituents. This may be
ameliorated given access to more experimental training
data for set of ligands with structural conservation in
the triphosphate and ribose moieties and greater diversity
among ribose substituents.
For ligands with the capacity for low-barrier intercon-
version between 2 0- and 3 0-ribose substituents, the
COMBINE model training aﬀorded systematic evalua-
tion of the comparison of the two isomeric forms, and
predicted that the majority of ligands in our training
set should adopt the 3 0-substitution form, in contrast
with prior modeling work,16 but corresponding well
with recent crystallographic evidence for MANT-
GTP.14 Comparing the manifold of predicted ligand
conformers of these ribose-modiﬁed ligands versus a pri-
or manifold of NRM nucleotides18 and the crystal struc-
tures derived from ATPaS-inhibitor AC versus the
analogous MANT-GTP structure has allowed us to pos-
it that a speciﬁc receptor relaxation occurs, primarily
involving an alternative conformation of the Arg 1029
side-chain, that diﬀerentially favors the 3 0-substitution
form.4. Methodology
The receptor structure model used herein for evaluating
AC inhibition by ribosyl-substituted nucleotides was
adapted from an X-ray crystal structure for AC in com-
plex with MANT-GTP (PDB ID: 1TL7).14 This is in
contrast to our previous work on non-ribosyl-modiﬁed
(NRM) nucleotides, in which we employed a receptor
model derived from an AC/ATPaS crystal structure.18
The receptor model was prepared by eliminating all res-
idues located more than 15.0 A˚ from the position of the
co-crystallized MANT-GTP ligand, leaving a total of
120 residues within the receptor model (a full list, includ-
ing relevant coeﬃcients, is provided in the supporting
information). The ligand itself was then also eliminated,
and the remaining structure was protonated to yield ion-
ic aspartate, glutamate, lysine, and arginine residues,
and all other atoms saturated to neutrality. Unrealistic
atomic contacts were alleviated by energetically mini-
mizing all hydrogen atom coordinates (heavy atoms spa-
tially ﬁxed) via the AMBER ’89 force ﬁeld and
corresponding charges,24 as implemented in the MOE
software suite.25 The AC receptor contains two metal
ions that, under normal physiological conditions,
include one Mg2+ and one Mn2+. The nature of these
ions has been identiﬁed as having a major eﬀect on
ligand binding aﬃnity14–16,18 and thus separate receptor
models were constructed for the normal (Mg2+ + Mn2+),
magnesium enriched (Mg2+ + Mg2+), and manganese
enriched (Mn2+ + Mn2+) species for which assay data
exist. As crystal structures have elucidated little impact
on the surrounding protein structure as a function of
receptor ion exchange,22 a structure of Mn2+ enriched
AC was obtained by simply substituting the native
Mg2+ receptor metal ion for a second Mn2+ ion. The
Mg2+ enriched model was obtained in an analogous
fashion. It should be noted that such a truncated model
(i.e., with the 15.0 A˚ cutoﬀ for residue retention),
while computationally expeditious, does preclude the
possibility of rigorous examination of receptor relaxa-
tion response eﬀects. We intend to address these eﬀects
in future work.
The collection of ligands examined in this study focused
primarily on nucleotide analogs, most with assorted
ribosyl modiﬁcations, for which experimental AC inhi-
bition data were available. Speciﬁcally, the manifold
included standard mono-, di-, and triphosphate (i.e.,
NMP, NDP, and NTP) nucleotides, plus some c-thio
analogs thereof (i.e., NTPcS), and others with amino
linkers between the b and c phosphates (i.e., NppNHp).
Ribosyl modiﬁcations include phosphate cyclization
(e.g., cAMP), unadorned 2 0-deoxy nucleotide analogs
(e.g., 2 0-d-UTP), and oxy-substituents including dip-
yrromethene boron diﬂuoride (BODIPY), MANT and
its n-hexyl (MAH) analog. The full set of ligands consid-
ered herein, along with observed experimental Ki data in
conjunction with inhibition constants (for both normal
and Mn2+-enriched AC) obtained from our previous
work,16 is reported in Table 1.
Structures for the ligands listed in Table 1 were pre-
pared via SYBYL26 and optimized using the Tripos
J. L. Wang et al. / Bioorg. Med. Chem. 15 (2007) 2993–3002 3001Force Field27 and Gasteiger–Marsili electrostatics28 as
implemented in SYBYL 7.2,26 taking account all
non-bonding forces to within an 8.0 A˚ cutoﬀ. Other
energetic and convergence settings were set to default val-
ues. All ligands were assumed to possess a fully ionized
phosphate tail, with the following net charges: triphos-
phate = 4, diphosphate = 3, monophosphate = 2.
All other atoms were protonated to neutrality.
Ligand–receptor complex structures were predicted via
Lamarkian genetic algorithms ﬂexible binding confor-
mational searches as implemented in AutoDock.29 100
poses were requested for each ligand, of which only
those that exhibited binding between the phosphate tail
and the receptor metal cations were retained for subse-
quent consideration. For structure–activity modeling,
the preliminary criterion for choosing a given ligand
pose was a ranking by AutoDock aﬃnity score. As is de-
scribed in the subsequent paragraph, however, the origi-
nal pose choice was iteratively reﬁned according to
capacity for optimizing the structure–activity partial
least squares (PLS) ﬁt.
For each complex, pairwise electrostatic and van der
Waals (VDW) terms were computed between the ligand
and each residue within the 15.0 A˚ radius receptor mod-
el. These terms were evaluated according to the
MMFF94 VDW parametrization,30 and electrostatics
derived from MMFF94 ligand atomic charges30 (as
implemented in SYBYL 7.1)26 and AMBER receptor
charges,24 all performed via the computer program
COMBSCORE. This program was developed in house,
encoding all electrostatic and VDW terms in the precise
form prescribed in the original MMFF94 publication.30
COMBSCORE test cases were validated relative to
VDW and electrostatic energies computed in SYBYL.26
The program source code and relevant sample input ﬁles
are provided in supporting information. Building on a
model from our earlier study31 and functionally adapted
from a prior project,31 the binding aﬃnity for each
ligand was then trained as a PLS ﬁt of desolvation terms
and the above enthalpic interactions (without any form
of variable rescaling) collectively expressed via the
following equation:
pK i ¼ 9 log10ðK iÞ
¼ cPðDPSAÞ þ cNðDNPSAÞ
þ
X
j
ceðjÞEelej þ cvðjÞEvdwj
 
þ K
as based on the comparative binding energy (COM-
BINE) type methodology.32 The ﬁrst two terms in this
expression, DPSA (the change in the ligand’s solvent
accessible polar surface area upon complexation) and
DNPSA (the corresponding change in non-polar surface
area), were chosen to reﬂect ligand desolvation eﬀects.
Eelei and E
vdw
i are electrostatic and VDW interaction
enthalpies arising between the ith residue and the
docked ligand. Finally, the regression coeﬃcients, cP,
cN, ce, and cv (for DPSA, DNPSA, E
ele
i , and E
vdw
i , respec-
tively), were computed via the Simca-P33 program, andK is a scaling constant generated from this regression
analysis.
As indicated previously, we iteratively reﬁned the above
COMBINE model by identifying ligands whose initial
pKi prediction deviated by more than 25% from the
experimental value, and replacing the initially selected
pose with the highest ranked structure for which a devi-
ation of less than 25% relative to experiment was possi-
ble. Note that the new conformer was only retained in
the model if it yielded an improved cross-validated
(Q2) correlation relative to experiment. In the event that
no pose was obtained satisfying these requirements, the
ligand was assumed to be an outlier and was omitted
from the model.
Since ribosyl-modiﬁed nucleotides are susceptible to
low-barrier interconversion between the 2 0- and 3 0-sub-
stituent form,34 our COMBINE analysis was applied
in a similar manner to predict which of the two isomers
was the most probable AC inhibitor. To accomplish
this, an initial PLS model was computed wherein both
the 2 0- and 3 0-substituted versions of each nucleotide
(except for 2 0-deoxy ligands, where only the 3 0-substitu-
tion is possible) were included. In each case, the criteria
of lower relative deviations between experiment and the-
ory, and improved Q2 performance were used to identify
the more internally consistent structure. This structure
was retained in the model and its poorer performing iso-
mer was then discarded.
For our analysis of receptor relaxation eﬀects, torsional
energies for the side-chains of select receptor residues of
interest were analyzed by clearing the receptor model of
all ligands and crystallographic waters, but retaining
in situ metal ions, as the latter are considered vital to
receptor function. The total potential energy of the sys-
tem was then evaluated using MOE with AMBER force
ﬁeld and charges for all conformers of the target torsion-
al degree of freedom along a 360 rotation with a 5
increment. All other bond lengths, angles, and dihedrals
were ﬁxed during such searches.Acknowledgments
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